Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease

Clinical Laboratory

Volumn 52, Issue 1-2, 2006, Pages 1-10

  Meier, Christian ^a,b   Meinhardt, Udo ^c   Greenfield, Jerry R ^c   De Winter, James ^a   Nguyen, Tuan V ^c   Dunstan, Colin R ^a   Seibel, Markus J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Bone turnover marker; Cathepsin K; Osteoporosis; Paget's disease

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG RESPONSE; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; OSTEOLYSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; POSTPRANDIAL STATE; PREVALENCE; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ALKALINE PHOSPHATASE; BONE RESORPTION; CATHEPSINS; CIGUATOXINS; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; OSTEITIS DEFORMANS; OSTEOPOROSIS, POSTMENOPAUSAL; STATISTICS, NONPARAMETRIC;

EID: 32644460848     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000;11(Suppl 6):S18-29.
2. Kafienah W, Bromme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 1998;331 (Pt 3):727-32.
3. Li Z, Yasuda Y, Li W, Bogyo M, Katz N, Gordon RE, Fields GB, Bromme D. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 2004;279:5470-9.
4. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8.
5. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998;95:13453-8.
6. Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654-63.
7. Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc (Tokyo) 2003 52:551-8.
8. Stroup GB, Lark MW, Veber DF, et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2001;16: 1739-46.
9. Wang D, Li W, Pechar M, Kopeckova P, Bromme D, Kopecek J. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. Int J Pharm;2004;277:73-9.
10. Skoumal M, Haberhauer G, Kolarz G, Hawa G, Woloszczuk W, Klingler A. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 2005;7:R65-70.
11. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997;12:1028-34.
12. Gomez B, Jr., Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995; 41:1560-6.
13. Greenfield JR, Samaras K, Hayward CS, Chisholm DJ, Campbell LV. Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. J Clin Endocrinol Metab 2005;90:661-72.
14. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995;206:89-96.
15. Inui T, Ishibashi O, Inaoka T, et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem 1997;272:8109-12.
16. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002 31:57-61.
17. Woitge HW, Seibel MJ, Ziegler R. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem 1996;42:1796-804.
18. Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366-71.
19. Hassager C, Colwell A, Assiri AM, Eastell R, Russell RG, Christiansen C Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin Endocrinol (Oxf) 1992; 37:45-50.
20. Seibel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993;8:881-9.
21. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-8.
22. Raisz L, Smith JA, Trahiotis M, et al. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 2000;11:615-20.
23. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
24. Meier C, Nguyen TV, Seibel MJ. Monitoring of antiresorptive therapy. In: Seibel MJ, Robins S, Bilezikian JP (eds.) Dynamics of Bone and Cartilage Metabolism, 2nd ed. 2005 Academic Press, San Diego.
25. Zaidi M, Troen B, Moonga BS, Abe E. Cathepsin K, osteoclastic resorption, and osteoporosis therapy. J Bone Miner Res 2001;16: 1747-9.
26. Sato Y, Sakai H, Kobayashi Y, Shibasaki Y, Sasaki T. Bisphosphonate administration alters subcellular localization of vacuolar-type H(+)-ATPase and cathepsin K in osteoclasts during experimental movement of rat molars. Anat Rec 2000;260:72-80.
27. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
28. Corisdeo S, Gyda M, Zaidi M, Moonga BS, Troen BR. New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem Biophys Res Commun 2001; 285:335-9.
29. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997;378:141-50.
30. Stubbs MT, Laber B, Bode W, et al. The refined 2.4 A X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. Embo J 1990;9:1939-47.
31. Kobori M, Ikeda Y, Nara H, et al. Large scale isolation of osteoclast-specific genes by an improved method involving the preparation of a subtracted cDNA library. Genes Cells 1998;3:459-75.
32. Lerner UH, Johansson L, Ranjso M, Rosenquist JB, Reinholt FP, Grubb A. Cystatin C, and inhibitor of bone resorption produced by osteoblasts. Acta Physiol Scand 1997;161:81-92.
33. Buhling F, Gerber A, Hackel C et al. Expression of cathepsin K in lung epithelial cells. Am J Respir Cell Mol Biol 1999;20:612-9.
34. Bromme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995;376:379-84.
35. Tepel C, Bromme D, Herzog V, Brix K. Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J Cell Sci 2000;113 Pt 24:4487-98.
36. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997;57:5386-90.